J. Thaddeus Beck - Researcher Profile

Publications

2 shown

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon , Patrick Neven , Stephen Chia +18 more

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast c...

2018 Journal of Clinical Oncology 1036 citations

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

David R. Spigel , Robert Weaver , J. Thaddeus Beck +16 more

2014 Journal of Thoracic Oncology 170 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,206
Institution: Oncology Hematology Care

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-3341-9903

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.